Journal article
Report from IPITA-TTS opinion leaders meeting on the future of β-cell replacement
ST Bartlett, JF Markmann, P Johnson, O Korsgren, BJ Hering, D Scharp, TWH Kay, J Bromberg, JS Odorico, GC Weir, N Bridges, R Kandaswamy, P Stock, P Friend, M Gotoh, DKC Cooper, CG Park, P O'Connell, C Stabler, S Matsumoto Show all
Transplantation | Published : 2016
Abstract
Biologic or biomechanical therapy capable of replacing the β cell mass has the potential to positively impact the health and well being of millions of people with insulindependent diabetes. Research in this area stands at a pivotal moment at which a number of viable strategies exist or are under development. Broad application depends on achieving both technical and financial feasibility. The ultimate goal of a "true cure," in which diabetic individuals achieve euglycemia with a single procedure associated with minimal risk, without long-termtoxic drugs, and unfettered by external devices and/or frequent monitoring, appears to still be some years away. However, dramatic progress has been achi..
View full abstractGrants
Awarded by National Institute of Diabetes and Digestive and Kidney Diseases
Funding Acknowledgements
This work was supported by generous educational grants by the Diabetes Research and Wellness Foundation and Dompe Pharmaceuticals. Additional funding was provided by beta-O2 Technologies LTD, Novartis Pharmaceuticals, Sanofi and the JDRF.